title: Compartment model predicts VEGF secretion and investigates the effects of VEGF trap in tumor-bearing mice.
abstract: Angiogenesis, the formation of new blood vessels from existing vasculature, is important in tumor growth and metastasis. A key regulator of angiogenesis is vascular endothelial growth factor (VEGF), which has been targeted in numerous anti-angiogenic therapies aimed at inhibiting tumor angiogenesis. Systems biology approaches, including computational modeling, are useful for understanding this complex biological process and can aid in the development of novel and effective therapeutics that target the VEGF family of proteins and receptors. We have developed a computational model of VEGF transport and kinetics in the tumor-bearing mouse, which includes three-compartments: normal tissue, blood, and tumor. The model simulates human tumor xenografts and includes human (VEGF121 and VEGF165) and mouse (VEGF120 and VEGF164) isoforms. The model incorporates molecular interactions between these VEGF isoforms and receptors (VEGFR1 and VEGFR2), as well as co-receptors (NRP1 and NRP2). We also include important soluble factors: soluble VEGFR1 (sFlt-1) and α-2-macroglobulin. The model accounts for transport via macromolecular transendothelial permeability, lymphatic flow, and plasma clearance. We have fit the model to available in vivo experimental data on the plasma concentration of free VEGF Trap and VEGF Trap bound to mouse and human VEGF in order to estimate the rates at which parenchymal cells (myocytes and tumor cells) and endothelial cells secrete VEGF. Interestingly, the predicted tumor VEGF secretion rates are significantly lower (0.007-0.023 molecules/cell/s, depending on the tumor microenvironment) than most reported in vitro measurements (0.03-2.65 molecules/cell/s). The optimized model is used to investigate the interstitial and plasma VEGF concentrations and the effect of the VEGF-neutralizing agent, VEGF Trap (aflibercept). This work complements experimental studies performed in mice and provides a framework with which to examine the effects of anti-VEGF agents, aiding in the optimization of such anti-angiogenic therapeutics as well as analysis of clinical data. The model predictions also have implications for biomarker discovery with anti-angiogenic therapies.
authors.affiliation: Department of Biomedical Engineering, Johns Hopkins University School of Medicine , Baltimore, MD , USA.
authors.forename: Stacey D
authors.initials: SD
authors.lastname: Finley
authors.forename: Manjima
authors.initials: M
authors.lastname: Dhar
authors.forename: Aleksander S
authors.initials: AS
authors.lastname: Popel
keywords: angiogenesis; anti-angiogenic therapy; cancer; computational model; mathematical model; systems biology; tumor xenograft model
references.citation: Cancer Res. 2000 Sep 1;60(17):4932-8
references.pmid: 10987309
references.citation: J Biol Chem. 2000 Sep 1;275(35):26690-5
references.pmid: 10842181
references.citation: Mol Cancer Ther. 2009 Jul;8(7):1761-71
references.pmid: 19567820
references.citation: Eur J Cancer. 1997 Jun;33(7):1108-13
references.pmid: 9376191
references.citation: Clin Colorectal Cancer. 2013 Jun;12(2):73-85
references.pmid: 23102896
references.citation: J Biol Chem. 2000 Sep 1;275(35):26806-11
references.pmid: 10862607
references.citation: J Orthop Res. 2011 Aug;29(8):1251-8
references.pmid: 21381098
references.citation: PLoS One. 2011 Jan 20;6(1):e16062
references.pmid: 21283766
references.citation: Am J Pathol. 2000 Apr;156(4):1363-80
references.pmid: 10751361
references.citation: J Magn Reson Imaging. 2002 Sep;16(3):289-99
references.pmid: 12205585
references.citation: Microcirculation. 2012 Feb;19(2):115-25
references.pmid: 22078005
references.citation: Pol J Pathol. 2003;54(1):53-9
references.pmid: 12817881
references.citation: J Appl Physiol (1985). 2007 Jun;102(6):2346-51
references.pmid: 17255365
references.citation: Biochem J. 2011 Jul 15;437(2):169-83
references.pmid: 21711246
references.citation: IEEE Trans Med Imaging. 2009 Jun;28(6):861-71
references.pmid: 19150783
references.citation: PLoS Comput Biol. 2006 Dec 29;2(12):e180
references.pmid: 17196035
references.citation: Cancer Res. 2001 Mar 1;61(5):1786-90
references.pmid: 11280723
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2205-18
references.pmid: 23669226
references.citation: Nat Rev Mol Cell Biol. 2006 May;7(5):359-71
references.pmid: 16633338
references.citation: J Appl Physiol (1985). 2005 Jun;98(6):2137-46
references.pmid: 15661835
references.citation: Nat Biotechnol. 2012 Jul 10;30(7):648-57
references.pmid: 22781694
references.citation: Physiol Rev. 2011 Jul;91(3):1071-121
references.pmid: 21742796
references.citation: Angiogenesis. 2012 Jun;15(2):171-85
references.pmid: 22302382
references.citation: J Physiol. 2007 Nov 15;585(Pt 1):231-9
references.pmid: 17884919
references.citation: Clin Cancer Res. 2012 Nov 15;18(22):6384-91
references.pmid: 23104894
references.citation: Cancer Res. 2006 Apr 15;66(8):4159-66
references.pmid: 16618737
references.citation: Int J Cancer. 2006 Dec 15;119(12):2795-802
references.pmid: 17019708
references.citation: Br J Cancer. 2007 Oct 8;97(7):978-85
references.pmid: 17912242
references.citation: Int J Gynecol Cancer. 2001 Mar-Apr;11(2):137-42
references.pmid: 11328412
references.citation: BMC Syst Biol. 2011 Nov 21;5:193
references.pmid: 22104283
references.citation: PLoS One. 2011;6(11):e27514
references.pmid: 22087332
references.citation: Biochem J. 1987 Dec 15;248(3):837-45
references.pmid: 2449173
references.citation: Cancer Res. 2007 Mar 1;67(5):2217-25
references.pmid: 17332352
references.citation: Am J Pathol. 2003 Nov;163(5):1801-15
references.pmid: 14578181
references.citation: Cancer Res. 2007 Jun 1;67(11):5505-12
references.pmid: 17545633
references.citation: Am J Physiol. 1970 Dec;219(6):1595-605
references.pmid: 5485678
references.citation: J Hypertens. 2010 Jun;28(6):1176-85
references.pmid: 20179634
references.citation: J Physiol. 2012 Feb 1;590(3):595-606
references.pmid: 22155930
references.citation: Transl Oncol. 2012 Apr;5(2):92-7
references.pmid: 22496925
references.citation: J Cell Sci. 2012 Feb 15;125(Pt 4):831-43
references.pmid: 22399811
references.citation: Exp Physiol. 2013 Feb;98(2):585-97
references.pmid: 22962287
references.citation: Nat Nanotechnol. 2012 Apr 08;7(6):383-8
references.pmid: 22484912
references.citation: Hum Pathol. 1998 Sep;29(9):910-4
references.pmid: 9744306
references.citation: Math Med Biol. 2012 Mar;29(1):85-94
references.pmid: 21266494
references.citation: Discov Med. 2010 Mar;9(46):179-84
references.pmid: 20350482
references.citation: Cancer Res. 2004 Nov 1;64(21):7822-35
references.pmid: 15520188
references.citation: J Biol Chem. 1996 Oct 4;271(40):24982-8
references.pmid: 8798779
references.citation: Breast Cancer Res Treat. 2006 Aug;98(3):315-27
references.pmid: 16541323
references.citation: Urol Res. 2003 Oct;31(5):335-40
references.pmid: 14574539
references.citation: Magn Reson Imaging. 2007 Jan;25(1):1-13
references.pmid: 17222711
references.citation: Nat Rev Cancer. 2010 Mar;10(3):221-30
references.pmid: 20179714
references.citation: Biochem J. 1973 Aug;133(4):709-24
references.pmid: 4201304
references.citation: NMR Biomed. 2012 Jul;25(7):935-42
references.pmid: 22190279
references.citation: Int J Mol Sci. 2012 Dec 20;14(1):88-107
references.pmid: 23344023
references.citation: PLoS One. 2009;4(4):e5108
references.pmid: 19352513
references.citation: Cold Spring Harb Perspect Med. 2012 Jun;2(6):a006411
references.pmid: 22675660
references.citation: Clin Cancer Res. 2002 Jul;8(7):2253-9
references.pmid: 12114428
references.citation: Lab Invest. 2000 Nov;80(11):1671-80
references.pmid: 11092527
references.citation: Transl Oncol. 2010 Feb;3(1):56-64
references.pmid: 20165696
references.citation: J Theor Biol. 2008 Sep 7;254(1):178-96
references.pmid: 18572196
references.citation: Nat Med. 1995 Jan;1(1):27-31
references.pmid: 7584949
references.citation: Int J Radiat Oncol Biol Phys. 2007 Apr 1;67(5):1526-37
references.pmid: 17234361
references.citation: J Biol Chem. 1981 Aug 10;256(15):8134-9
references.pmid: 6167573
references.citation: J Natl Cancer Inst. 2013 Jun 5;105(11):762-5
references.pmid: 23670727
references.citation: Nanotechnology. 2011 Dec 9;22(49):494004
references.pmid: 22101316
references.citation: Nature. 2012 Mar 18;484(7392):110-4
references.pmid: 22426001
references.citation: Blood. 2011 Aug 4;118(5):1359-69
references.pmid: 21680800
references.citation: Microcirculation. 2008 Nov;15(8):739-51
references.pmid: 18720228
references.citation: Ann Biomed Eng. 2001 Dec;29(12):1150-8
references.pmid: 11853267
references.citation: Int J Cancer. 2006 Oct 1;119(7):1519-29
references.pmid: 16671089
references.citation: Int J Cancer. 1991 May 30;48(3):399-403
references.pmid: 1710207
references.citation: NMR Biomed. 2004 Jun;17(4):170-80
references.pmid: 15229930
references.citation: Cancer Treat Rev. 2012 Aug;38(5):484-93
references.pmid: 22264850
references.citation: Mol Cancer. 2010 Feb 22;9:42
references.pmid: 20175926
references.citation: Cancer Cell Int. 2005 Jul 26;5:23
references.pmid: 16045802
references.citation: Growth Factors. 2012 Oct;30(5):283-96
references.pmid: 22817635
references.citation: PLoS One. 2013 Jun 21;8(6):e67438
references.pmid: 23805312
references.citation: BMC Syst Biol. 2008 Aug 19;2:77
references.pmid: 18713470
references.citation: Cancer Res. 2004 Sep 15;64(18):6616-25
references.pmid: 15374976
references.citation: Scand J Clin Lab Invest. 1993 Oct;53(6):639-48
references.pmid: 7505478
references.citation: PLoS One. 2011;6(8):e22745
references.pmid: 21826202
references.citation: Int J Cancer. 1999 Dec 10;83(6):798-802
references.pmid: 10597197
references.citation: Dev Dyn. 2001 Feb;220(2):112-21
references.pmid: 11169844
references.citation: Clin Chem. 2007 Aug;53(8):1433-9
references.pmid: 17599955
references.citation: Circ Res. 2011 Jul 22;109(3):246-7
references.pmid: 21778432
references.citation: J Biol Chem. 2003 Apr 11;278(15):12605-8
references.pmid: 12538598
references.citation: Circ Res. 2004 Jun 11;94(11):1443-50
references.pmid: 15192038
references.citation: J Surg Res. 1997 Feb 1;67(2):147-54
references.pmid: 9073561
references.citation: Ann Biomed Eng. 2012 Nov;40(11):2425-41
references.pmid: 22565817
references.citation: J Physiol. 2010 Oct 1;588(Pt 19):3833-45
references.pmid: 20693292
references.citation: J Natl Cancer Inst. 2013 Jun 5;105(11):802-11
references.pmid: 23670728
references.citation: J Immunol Methods. 1990 Jan 24;126(1):13-20
references.pmid: 1689358
references.citation: Cell Prolif. 1995 Aug;28(8):415-30
references.pmid: 7548442
references.citation: Clin Chem. 2001 Apr;47(4):617-23
references.pmid: 11274009
references.citation: Nat Rev Clin Oncol. 2012 Feb 14;9(5):297-303
references.pmid: 22330688
references.citation: Cell. 2007 Aug 24;130(4):691-703
references.pmid: 17719546
references.citation: AAPS J. 2012 Sep;14(3):500-9
references.pmid: 22547351
references.citation: J Clin Oncol. 2009 Jun 20;27(18):3020-6
references.pmid: 19470921
references.citation: Future Oncol. 2009 Jun;5(5):703-12
references.pmid: 19519209
references.citation: Proc Natl Acad Sci U S A. 2007 Nov 20;104(47):18363-70
references.pmid: 18000042
references.citation: Int J Mol Sci. 2013 Apr 29;14(5):9338-64
references.pmid: 23629668
references.citation: IEEE Eng Med Biol Mag. 2009 Mar-Apr;28(2):14-31
references.pmid: 19349248
references.citation: Am J Physiol Regul Integr Comp Physiol. 2008 Mar;294(3):R975-82
references.pmid: 18094062
references.citation: Pol J Pathol. 2002;53(4):183-8
references.pmid: 12597334
references.citation: Cancer Chemother Pharmacol. 2003 Apr;51(4):321-7
references.pmid: 12721760
references.citation: Clin Cancer Res. 2012 Nov 15;18(22):6306-14
references.pmid: 23014526
references.citation: Cell Cycle. 2008 Dec;7(23):3747-58
references.pmid: 19029832